<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-107814</identifier>
<setSpec>1130-6343</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy associated toxicity in treatment of peritoneal carcinomatosis</dc:title>
<dc:description xml:lang="en">Introduction Peritoneal carcinomatosis is a form of intra-abdominal dissemination of several tumours, which is associated with a poor prognosis. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is an alternative treatment. The aim of this study is to describe the toxicity associated with this procedure in patients with peritoneal carcinomatosis. Method We conducted a descriptive, retrospective, single-centre study, including all patients undergoing this procedure between December 2007 and January 2010. The following data were recorded: anthropometric data, personal and surgical events, indication, previous treatments, extent of carcinomatosis, intervention duration, hospital stay, and type of complications and/or adverse events following application of the multidisciplinary treatment. Results We performed 46 interventions on 45 patients diagnosed with peritoneal carcinomatosis from different causes, mainly ovarian cancer (83%). Paclitaxel was the most-used drug (35 interventions). There was no associated mortality, the average intervention time was 6.4hours and the average hospital stay 7days. We recorded adverse effects for 42 procedures, being grade 3-4 in 28.3% of the patients. The severe adverse events were: 10.9% gastrointestinal, 10.9% infectious, 6.5% haemorrhage or bleeding, 6.5% medullary toxicity, 4.4% respiratory, 2.2% coagulation and 2.2% hepatobiliary disorders. One patient developed grade III neutropaenia, probably associated with cisplatin. Conclusion The morbidity and mortality is in line with the average of published studies, and has mainly been attributed to surgical complications. Toxicity data lower than other studies can be due to using more tolerable chemotherapy regimens, not including drug combinations and given that paclitaxel was the main drug (AU)</dc:description>
<dc:creator>Mancebo-González, A</dc:creator>
<dc:creator>Díaz-Carrasco, M. S</dc:creator>
<dc:creator>Cascales-Campos, P</dc:creator>
<dc:creator>Rubia, A. de la</dc:creator>
<dc:creator>Gil Martínez, J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción La carcinomatosis peritoneal es una forma de diseminación intraabdominal de diversos tumores, asociada con mal pronóstico. La realización de cirugia citorreductora y administración de quimioterapia intraperitoneal hipertérmica constituye una alternativa para su tratamiento. El objetivo del estudio es describir la toxicidad derivada del procedimiento en pacientes diagnosticados de carcinomatosis peritoneal. Métodos Estudio descriptivo, retrospectivo, unicéntrico, incluyendo todos los pacientes sometidos al procedimiento, entre diciembre de 2007 y enero de 2010. Se registraron: datos antropométricos, antecedentes personales y quirúrgicos, indicación, tratamientos previos, grado de carcinomatosis, duración de la intervención, estancia hospitalaria, así como el tipo de complicaciones y/o eventos adversos tras la aplicación del tratamiento multidisciplinario. Resultados: Se realizaron 46 intervenciones en 45 pacientes diagnosticados de carcinomatosis peritoneal de diferentes etiologías, mayoritariamente cáncer de ovario (83%). El fármaco más utilizado fue paclitaxel (35 intervenciones). No hubo mortalidad asociada, el tiempo medio de intervención fue 6,4h y la estancia media hospitalaria 7 días. Se registraron eventos adversos en 42 procedimientos, siendo de grado 3-4 en un 28,3% de los pacientes. Las incidencias de reacciones severas fueron: 10,9% gastrointestinales, 10,9% (..) (AU)</dc:description>
<dc:source>Farm Hosp;36(2): 60-67, Mar. -Abr. 2012. tab</dc:source>
<dc:identifier>ibc-107814</dc:identifier>
<dc:title xml:lang="es">Toxicidad asociada a la cirugía citorreductora y quimioterapia intraperitoneal hipertérmica en el tratamiento de la carcinomatosis peritoneal</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d^s22012</dc:subject>
<dc:subject>^d974^s22068</dc:subject>
<dc:subject>^d10724^s22057</dc:subject>
<dc:subject>^d7158^s22074</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:type>article</dc:type>
<dc:date>201204</dc:date>
</metadata>
</record>
</ibecs-document>
